What is the current stock price of Neumora Therapeutics, Inc. Common Stock (NMRA)?

As of the latest market data, Neumora Therapeutics, Inc. Common Stock (NMRA) is trading at $2.04. The stock has seen a loss of -1.92% today.

Does Neumora Therapeutics, Inc. Common Stock (NMRA) pay a dividend?

Based on current data, Neumora Therapeutics, Inc. Common Stock does not have a confirmed active dividend policy.

What is the market cap of Neumora Therapeutics, Inc. Common Stock?

The current market capitalization of Neumora Therapeutics, Inc. Common Stock (NMRA) is approximately unavailable.

NMRA

Neumora Therapeutics, Inc. Common Stock·Healthcare

2.04

1.923%(−0.04)

Market Closed

2.23

9.314%(+0.19)

After Hours

Last Updated: — ET

52W L: $0.6152W H: $3.65

NMRA NEWS

globenewswire.com

5d ago

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m.

globenewswire.com

Apr 1

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

defenseworld.net

Mar 31

Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) was the target of some unusual options trading activity on Monday. Stock traders acquired 2,812 call options on the company. This is an increase of 309% compared to the average daily volume of 687 call options. Key Neumora Therapeutics News Here are the key news stories impacting

seekingalpha.com

Mar 30

Neumora Therapeutics: Downgrading After Navacaprant Development Setback

Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint. KOASTAL-2 and KOASTAL-3 studies for navacaprant in MDD have increased enrollment; topline data is expected in Q2 2026, but success remains uncertain. NMRA-511 showed a promising signal in phase 1b for Alzheimer's Disease agitation, with an enhanced effect in patients with elevated anxiety.

seekingalpha.com

Mar 30

Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 30

Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

110

IPO Date

2023-09-15

Beta

3.12

Websitewww.neumoratx.com↗